Idursulfase

Idursulfase (brand name Elaprase), manufactured by Takeda, is a drug used to treat Hunter syndrome (also called MPS-II).^[2] It is a purified form of iduronate-2-sulfatase, a lysosomal enzyme, and is produced by recombinant DNA technology in a human cell line.

Idursulfase

Clinical data
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN
ATC code	A16AB09 (WHO)
Legal status
Legal status	US: WARNING[1]
Identifiers
CAS Number	50936-59-9 Y
DrugBank	DB01271 Y
ChemSpider	none
UNII	5W8JGG2651
KEGG	D04499 Y
ChEMBL	ChEMBL1201826 N
NY (what is this?)  (verify)

It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.^[3][4][5]

References

1. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
2. Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. doi:10.1016/j.ymgme.2007.03.003. PMID 17459751.
3. "Drug approved to treat rare but potentially deadly disease". Archived from the original on 2011-02-24. Retrieved 2011-04-29.
4. Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010
5. , Barbara Kollmeyer, Marketwatch, Fed. 3, 2016

External links

• idursulfase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)